Similarly, the activation of compensatory feedback loops of ERBB3 has been identified as a mechanism of resistance to MEK inhibition in KRAS-mutant CRC, which potentially could be overcome by combinatorial treatment [133]. Here, KRAS is linked to colorectal carcinoma.